OpGen, Inc., a prominent player in the biotechnology sector, has continued to make significant strides in the field of microbial genetics analysis. As a company operating within the Health Care sector, OpGen has carved out a niche by offering a comprehensive platform for automated and microbial whole genome analysis. This platform integrates comparative genomics, whole genome sequence assembly, and strain characterization, all within the laboratory setting. Such capabilities have positioned OpGen as a critical resource for customers nationwide, who rely on its advanced technologies for microbial research and diagnostics.
As of November 30, 2025, OpGen’s stock is traded on the OTC Bulletin Board, with a close price of $8.15. The company’s market capitalization stands at approximately $82,080,976, reflecting its stable presence in the biotechnology industry. Over the past year, OpGen’s stock has experienced fluctuations, reaching a 52-week high of $8.50 and a low of $0.0001 on October 22, 2025. Despite these variations, the company maintains a price-to-earnings ratio of 11.26, indicating a balanced valuation in the eyes of investors.
Founded with an Initial Public Offering (IPO) on May 5, 2015, OpGen has since expanded its reach and technological capabilities. The company’s commitment to innovation is evident in its continuous development of tools that enhance the understanding of microbial genetics. By providing a robust platform for genomic analysis, OpGen supports a wide range of applications, from clinical diagnostics to environmental microbiology.
OpGen’s strategic focus on integrating cutting-edge technologies into its platform has not only solidified its position in the market but also attracted a diverse customer base. The company’s ability to deliver precise and comprehensive genomic data is crucial for advancing research and development in the health care sector. As the demand for genomic analysis continues to grow, OpGen is well-positioned to meet the needs of its clients and contribute to the broader field of microbial genetics.
In summary, OpGen, Inc. remains a key player in the biotechnology industry, driven by its innovative approach to microbial genetics analysis. With a strong market presence and a commitment to technological advancement, the company is poised for continued growth and success in the evolving landscape of health care and biotechnology.
